Faced with mounting lawsuits targeting the alleged downplay of severe gastrointestinal side effects of the drugs Ozempic and Wegovy, the manufacturers have been pulled under the limelight. Many lawsuits accuse these manufacturers, particularly Novo Nordisk AS and other similar companies, of underplaying these severe side effects. Originally created as a diabetes drug to regulate blood sugar by slowing the digestion system, the demand for these drugs increased when they became associated with weight loss, inviting new users and consequently, new cases of side effects.
In response to these contentious issues, a federal judge overseeing the litigation has appointed eight firms to leadership roles on the plaintiffs’ committee. This high-profile lineup includes well-known firms like Motley Rice, signifying a solid backing for the plaintiffs in this legal battle.
For more details, you can read the full news piece.